Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers

Completed · Phase 2

Conditions studied: Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: Thalidomide may kill tumor cells by stopping the growth of new blood vessels to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and cyclophosphamide in treating children who have recurrent or refractory childhood cancers.

Key facts

Study ID

NCT00003754

Run by

Memorial Sloan Kettering Cancer Center

Starts

1998-09-01

Expected to finish

2001-07-01

Last updated by the study team

2013-06-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.